On 22 February 2018, orphan designation (EU/3/18/1977) was granted by the European Commission to GW Research Ltd, United Kingdom, for cannabidivarin for the treatment of fragile X syndrome.
The sponsorship was transferred to GW Pharma (International) B.V., the Netherlands, in April 2019.
|Disease / condition||
Treatment of fragile X syndrome
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;